Business Wire

Merck Invests € 62 Million in New Quality Control Facility in Darmstadt, Germany

Share

Merck, a leading science and technology company, announces an investment of € 62 million at its Darmstadt headquarters in a new quality control building for its Life Science business. The facility will bring together approximately 135 employees across several departments into one collaborative state-of-the-art space. The nearly 10,000 square meter building is scheduled for completion by mid-2025. The new building is part of an investment program at the Darmstadt site: Merck will invest a total of around € 1.5 billion here by 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611541316/en/

Architect's rendering of Merck Life Science's new quality control building now under construction. (Photo: Business Wire)

“Quality plays an essential role in our purpose to impact life and health with science. The quality, compliance and business support are fundamental to our innovative Life Science products, services and digital offerings and make us a trusted partner to our stakeholders,” said Robert Nass, Head of Quality & Regulatory Management, Life Science business of Merck. “Our new quality control facility is a reflection of our commitment to deliver the highest quality and safest products to our customers and the patients they serve.”

Quality control is an essential step to ensure the safety of life science products used in the research, discovery, and manufacture of medicines. During the quality control process, products are tested for purity, allowing for the detection and removal of any harmful substances. Merck’s Life Science business has more than 25 labs specializing in the relevant methods.

Built to meet the German Sustainable Building Council GOLD standard for sustainability, the facility will feature regenerative energy generation (self-sufficient) and low-CO2 construction, as well as comply to special safety requirements for genetic engineering, biology laboratories, as well as dust-free labs that require specific hygiene protocols. The labs will be GMP-compliant.

Darmstadt is one of Merck's most important research and development centers for life science technologies. Over the next ten years, approximately one-fifth of the Life Science business’s sales from new products are expected to come from here. The goal is to expand Life Science's capacities and capabilities to meet the growing global demand for medicines.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240611541316/en/

Contacts

Media Relations
rachel.bloom-baglin@merckgroup.com
Phone: +49 (6151) 72-44461

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REPLY: AIRA Challenge 2024 Prize awarded to Roboverse Reply for Mobile Robot Control via VR Glasses24.6.2024 11:00:00 EEST | Press release

Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. The competition invited world-leading experts to develop innovative solutions for enabling the remote control of mobile robots during autonomous inspections in production environments. Roboverse Reply’s platform demonstrates how Artificial Intelligence and human expertise can be combined to tackle challenging industrial tasks in real-world applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624606163/en/ Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. (Graphic: Business Wire) The final of the AIRA Challenge took place for the second time at ACHEMA, the world's largest trade fair fo

Takeda Announces Approval of LIVTENCITY ® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies24.6.2024 10:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval of LIVTENCITY in Japan, which will provide the transplant community with a new option for treatment of post-transplant CMV infection in patients refractory to other therapies,” said Yasushi Kajii, Head, R&D Japan Region at Takeda. “A diagnosis of CMV infection can be particularly challenging for patients, and serious complications such as increased organ rejection and hospitalization rates can occur, when not successfully treated. We believe LIVTENCITY has the potential to help address the challenges faced by people with post-transplant CMV and

Megaport and Lufthansa Systems Announce Landmark Partnership to Accelerate Airline Digital Transformation24.6.2024 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, and Lufthansa Systems, a leading aviation IT provider, today announced a new partnership that will accelerate digital transformation in the aviation industry. The strategic partnership will see Lufthansa Systems leverage Megaport’s global Software Defined Network (SDN) to securely and reliably move the global aviation cloud from a single cloud to multiple clouds by moving core routing from cloud to Megaport. Megaport will also facilitate a secure aviation customer landing zone to expedite peering with other airlines and exchanging data. Lufthansa Systems provides IT services to over 350 airlines worldwide. Its Global Aviation Cloud initiative aims to virtualise mission-critical airline applications and transition them to the cloud. Using Megaport’s private connectivity from resilient data centres, virtual firewalls, and virtual routing, Lufthansa Systems can securely and reliably connect

Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)24.6.2024 09:00:00 EEST | Press release

Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/ Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available. Seroba joined the consortium of investors leading the planned second closing of the Series B financi

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 05:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye